S

SCI Pharmtech Inc
TWSE:4119

Watchlist Manager
SCI Pharmtech Inc
TWSE:4119
Watchlist
Price: 82.9 TWD -0.12% Market Closed
Market Cap: 9.9B TWD
SCI Pharmtech Inc
/
Income Statement
/
Income from Continuing Operations

SCI Pharmtech Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCI Pharmtech Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
SCI Pharmtech Inc
TWSE:4119
Income from Continuing Operations
NT$484.2m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
7%
Y
YungShin Global Holding Corp
TWSE:3705
Income from Continuing Operations
NT$1.1B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
4%
Formosa Laboratories Inc
TWSE:4746
Income from Continuing Operations
NT$255.5m
CAGR 3-Years
-39%
CAGR 5-Years
15%
CAGR 10-Years
0%
ScinoPharm Taiwan Ltd
TWSE:1789
Income from Continuing Operations
NT$399.4m
CAGR 3-Years
26%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Income from Continuing Operations
NT$4.3B
CAGR 3-Years
43%
CAGR 5-Years
46%
CAGR 10-Years
N/A
Standard Chem & Pharm Co Ltd
TWSE:1720
Income from Continuing Operations
NT$1.2B
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
14%

SCI Pharmtech Inc
Glance View

Market Cap
9.9B TWD
Industry
Pharmaceuticals

SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others

Intrinsic Value
50.53 TWD
Overvaluation 39%
Intrinsic Value
Price
S
What is Intrinsic Value?

See Also

What is SCI Pharmtech Inc's Income from Continuing Operations?
Income from Continuing Operations
484.2m TWD

Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Income from Continuing Operations amounts to 484.2m TWD.

What is SCI Pharmtech Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%

Over the last year, the Income from Continuing Operations growth was 28%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.